Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-04-30

Development of a dna vector for the treatment of haemophilia a using gene therapy technologies

Ziel



Current treatment regimes for Haemophilia A involve the frequent administration of plasma derived or recombinant human Factor VIII (hFVIII). However, treatment is restricted by the availability, short half-life and high cost of purifled hFVIII. Therefore, we propose to develop a clinical gene therapy protocol suitable for the treatment of patients suffering from Haemophilia A.
To achieve this we propose to assess a number of eukaryotic promoters for cell type specificity in addition to persistence of on in lineages derived from hematopoietic stem cells. These promoters will then be transferred into a retroviral backbone where they will regulate expression of the hFVIII cDNA. Hematopoietic cells will be obtained from patients bone marrow, transduced in vitro, prior to reimplantation into the patients. Peripheral blood cells derived from the transduced hematopoietic stem cells are expected to secrete hFvIII directly into the plasma resulting in the systemic correction of the condition.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Daten nicht verfügbar

Finanzierungsplan

RGI - Research grants (individual fellowships)

Koordinator

KAROLINSKA INSTITUTE
EU-Beitrag
Keine Daten
Adresse
Haelsvaegen 7
141 57 Huddinge
Schweden
Gesamtkosten
Keine Daten

Beteiligte (1)